Invst Guru is your bi-weekly digest that explores the dynamics of equity crowdfunding. Delivered every Tuesday and Sunday, we connect startups with the power of the crowd, providing investors with access to groundbreaking ventures.

In each issue of Invst Guru, we'll spotlight the latest trends, share success stories, and offer insights from industry leaders. We aim to equip you with the knowledge and opportunities to participate effectively in equity crowdfunding, whether you're looking to fund your innovative startup or invest in potential unicorns.

Editor’s note
This section is for informational purposes only. This content does not constitute investment advice or a solicitation to invest. Invst Guru is not affiliated with Ezalife, StartEngine, or any broker-dealer. Any investment under Regulation Crowdfunding involves significant risk, including the possible loss of capital. Prospective investors should review the company’s official Form C and offering materials filed with the SEC before making any investment decision. If Ezalife is conducting a live Regulation Crowdfunding offering, all investments must be made exclusively through its registered funding portal. No offering terms are included in this newsletter.

Some healthcare problems hide in plain sight. Families face them daily. Hospitals absorb the cost. Feeding tube dislodgement is one of them.

Each year, more than one million families in the United States leave hospitals with a child or loved one fitted with a gastrostomy button. This low-profile feeding tube delivers nutrition, hydration, and medication directly to the stomach. After discharge, caregivers typically use tape and gauze to secure the device. This approach has changed little over the decades.

Ezalife was built to address this gap. The company developed the Button Huggie®, an FDA-registered medical device designed to secure gastrostomy buttons in home care settings. The product targets a specific clinical challenge commonly managed rather than solved.

This campaign brings that solution into the equity crowdfunding market.

Accidental feeding tube dislodgement often triggers a rapid chain of events. When a gastrostomy button is dislodged, the stoma may begin to close within hours. Families frequently seek emergency care for reinsertion. Children experience pain and distress. Caregivers face disruption and stress.

Tape-based securement introduces additional issues. Adhesives may irritate skin. Leakage may increase infection risk. Granulation tissue may form. Daily tape removal adds discomfort and time to already demanding care routines.

These challenges are familiar in pediatric hospitals. They often receive less attention once patients transition home.

Dr. Steven Moulton is a pediatric surgeon at Children’s Hospital Colorado and a professor of surgery at the University of Colorado School of Medicine. He has treated hundreds of children with feeding tubes and has observed recurring complications related to securement after discharge.

The concept for the Button Huggie® emerged from repeated clinical exposure to these outcomes. Families frequently contacted care teams after discharge. Standard instructions relied on tape.

Dr. Moulton partnered with engineers at the University of Colorado to design a device to place gastrostomy buttons securely. The stated goal was to reduce dislodgement and improve daily care routines.

The Button Huggie® became Ezalife’s first commercial product.

The Button Huggie® is a disposable medical securement device designed to stabilize gastrostomy buttons without adhesive tape, keeping them in place against the skin. The device uses mechanical securement while allowing access for cleaning and feeding.

Regulatory status
FDA-registered medical device. Classified as Class II and listed as 510(k) exempt for over-the-counter sale.

Intellectual property
Protected by a granted U.S. patent with eighteen claims. Additional international patent applications are pending.

These factors influence market access and competitive positioning. They do not guarantee commercial success.

Ezalife completed a randomized, IRB-approved clinical study across four children’s hospitals. The study enrolled 185 patients and evaluated feeding tube dislodgement as the primary endpoint.

According to internal study data, patients using the Button Huggie® experienced a lower rate of gastrostomy button dislodgement than those using tape and gauze. The company reports a 77 percent reduction relative to standard care. The analysis reached statistical significance in September 2025.

These findings reflect internal study results. They have not been peer reviewed. They do not predict future clinical outcomes, regulatory determinations, or commercial adoption. Secondary observations included higher caregiver satisfaction and reduced daily care time, as reported by study participants.

Ezalife launched direct-to-consumer e-commerce sales in August 2025. Initial demand originated from a pre-launch caregiver waitlist.

Reported sales figures include:
Launch day sales of approximately $8,600
First 30 days of roughly $10,800
October sales exceeded $13,000

These figures reflect early customer adoption. They do not indicate future revenue levels or long-term scalability.

Ezalife currently sells a one-month supply kit priced at $99 through its online store. Feeding tubes often remain in place for extended periods, which may support repeat purchases depending on individual patient circumstances.

Planned initiatives include:
Monthly subscription options
Multi-month supply bundles
Exploration of prescription-based distribution
Exploration of insurance reimbursement and hospital-to-home channels

These initiatives are plans rather than guarantees. Timing and outcomes depend on regulatory, reimbursement, and operational factors.

More than one million gastrostomy buttons are placed annually in the United States. An estimated 1.6 million patients worldwide use gastrostomy buttons at any given time. Ezalife estimates a total addressable market of approximately $1.9 billion annually for feeding-tube securement, based on internal assumptions. Actual addressable and obtainable markets may differ materially.

Additional potential use cases include geriatric care and the care of patients with chronic conditions requiring long-term enteral feeding.

The Button Huggie® represents the company’s first product. Additional securement concepts for other medical devices remain under development and are subject to technical, regulatory, and commercialization risk.

Dr. Steven Moulton, Founder and Chief Medical Officer
Pediatric surgeon with academic and clinical experience relevant to product design and hospital workflows.

John Patrick Allen, Chief Executive Officer
Career executive with experience building and scaling organizations across medical technology and institutional sales environments.

Kara Katharine Fagan, Chief Marketing Officer
Marketing executive with experience across consumer and enterprise go-to-market strategies.

Ezalife has raised approximately $1.6 million from institutional sources, including Children’s Hospital Colorado and the University of Colorado. The company has also received more than $600,000 in non-dilutive grants and awards. Past funding does not ensure future capital availability.

Ezalife presents a focused medical device concept grounded in clinical experience, early internal validation, and initial commercial activity. The opportunity depends on execution, reimbursement progress, and adoption beyond early users. The risks reflect the realities of regulated healthcare markets and early-stage companies.

As always, informed investing begins with careful review of official offering materials and risk disclosures filed with the SEC.

Investing in startups is speculative, involves a high degree of risk, and investors should be able to bear the loss of their entire investment. All investments must be made through the registered funding portal.

This newsletter is for informational purposes only and does not constitute investment advice or a solicitation to invest. Invst Guru is not affiliated with Ezalife, StartEngine, or any broker-dealer. Any investment in private or early-stage companies involves risk, including the potential loss of your entire investment. All investments in Ezalife must be made through its official Regulation Crowdfunding (Reg CF) campaign page on StartEngine. No investment terms are included in this newsletter. For full offering details, risk factors, and disclosures, please review the company’s official Form C filing and offering page.